CoChat
Sign Up
Cited by 352Liver Disease Diagnosis and TreatmentProbiotics and Fermented FoodsGut microbiota and health

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis

Open access
Ma, Yan-Yan·2013·World Journal of Gastroenterology
DOI 10.3748/wjg.v19.i40.6911PMC PMC3812493
Open this paper in CoChat — free accountOpen PDF

Abstract

AIM: To investigate the relationship between the gut-liver axis and nonalcoholic fatty liver disease (NAFLD), we performed a meta-analysis to evaluate the effects of probiotic therapy in NAFLD. METHODS: We searched PubMed, Medline, Embase, Web of Science, the Cochrane Library and Chinese Biomedicine Database for all relevant randomized controlled trials on probiotics in patients with NAFLD/nonalcoholic steatohepatitis (NASH). A statistical analysis was performed using RevMan 5.0 software. RESULTS: Four randomized trials involving 134 NAFLD/NASH patients were included. The results showed that probiotic therapy significantly decreased alanine aminotransferase (ALT), aspartate transaminase (AST), total-cholesterol (T-chol), high density lipoprotein (HDL), tumor necrosis factor (TNF)-α and homeostasis model assessment of insulin resistance (HOMA-IR) [ALT: weighted mean difference (WMD) -23.71, 95%CI: -33.46--13.95, P < 0.00001; AST: WMD -19.77, 95%CI: -32.55--7.00, P = 0.002; T-chol: WMD -0.28, 95%CI: -0.55--0.01, P = 0.04; HDL: WMD -0.09, 95%CI: -0.16-0.01, P = 0.03; TNF-α: WMD -0.32, 95%CI: -0.48--0.17, P < 0.0001; HOMA-IR: WMD -0.46, 95%CI: -0.73--0.19, P = 0.0008]. However, the use of probiotics was not associated with changes in body mass index (BMI), glucose (GLU) and low density lipoprotein (LDL) (BMI: WMD 0.05, 95%CI: -0.18-0.29, P = 0.64; GLU: WMD 0.05, 95%CI: -0.25-0.35, P = 0.76; LDL: WMD -0.38, 95%CI: -0.78-0.02, P = 0.06). CONCLUSION: Probiotic therapies can reduce liver aminotransferases, total-cholesterol, TNF-α and improve insulin resistance in NAFLD patients. Modulation of the gut microbiota represents a new treatment for NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3748/wjg.v19.i40.6911

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Salminen S. Uniqueness of probiotic strains. IDF Nutr News- letter 1996; 5: 16-18 13
  2. Hofacre CL, Mathis GF, Quiroz MA. Natural alternatives to prevent necrotic enteritis. Int Poult Prod 2005; 13: 7-9 60

Cited by

Sorted by citations

See all 352

Related

See all

Metadata

Authors
Ma, Y.-Y.
Venue
World Journal of Gastroenterology
Publisher
Baishideng Publishing Group Inc.
Published
2013
Volume
19
Issue
40
Pages
6911
ISSN
1007-9327 (ISSN-L)
DOI
10.3748/wjg.v19.i40.6911
PMC
PMC3812493
OpenAlex
W2151623669
Cited by
352
References
63
Citations by year
2026: 7 · 2025: 21 · 2024: 23 · 2023: 23 · 2022: 26 · 2021: 39 · 2020: 19 · 2019: 35 · 2018: 24 · 2017: 42 · 2016: 24 · 2015: 42 · 2014: 26 · 2013: 1
FWCI
3.67
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • World Journal of Gastroenterology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
probiotics, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, gut-liver axis, alanine aminotransferase, aspartate aminotransferase, insulin resistance, TNF-α, serum cholesterol, HDL cholesterol, LDL cholesterol, body mass index, glucose, liver enzymes, dyslipidemia, inflammation
MeSH terms
Fatty Liver, Humans, Insulin Resistance, Intestines, Liver, Chi-Square Distribution, Odds Ratio, Treatment Outcome, Probiotics, Lipid Metabolism, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review